Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:51:47 EDT Sun 08 Jun 2025
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q0.10.878·1.032.00.9848+0.05836.3463.74188440.93  1.06  0.936.89  0.635819:49:40May 0515 min RT 2¢

Recent Trades - Last 10 of 844
Time ETExPriceChangeVolume
19:49:40Q0.960.03351
19:39:32Q0.98490.05843
19:33:26Q0.9850.0585500
18:42:45Q0.9850.058520
18:37:37Q0.9850.058510
18:29:39Q0.9850.0585150
18:23:43Q0.9850.058575
17:49:07Q0.9850.058550
17:04:05Q0.98470.058240
16:40:28Q0.98480.05835

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-05 08:00U:IBIONews ReleaseiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
2025-05-02 08:00U:IBIONews ReleaseiBio Reports Fiscal Third Quarter 2025 Financial Results
2025-04-29 13:44U:IBIONews ReleaseiBio Raises $6.2 Million Through Warrant Inducement Transaction
2025-04-22 08:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
2025-04-07 07:00U:IBIONews ReleaseiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
2025-02-19 16:05U:IBIONews ReleaseiBio to Begin Trading on the Nasdaq Stock Exchange
2025-02-10 16:05U:IBIONews ReleaseiBio Reports Fiscal Second Quarter 2025 Financial Results
2025-01-13 07:00U:IBIONews ReleaseiBio Announces New Investments from Board Members and Officers
2025-01-07 07:00U:IBIONews ReleaseiBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
2025-01-02 07:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
2024-11-25 08:00U:IBIONews ReleaseiBio Strengthens Board with Appointment of Two New Independent Directors
2024-11-12 16:05U:IBIONews ReleaseiBio Reports Fiscal First Quarter 2025 Financial Results
2024-10-10 08:00U:IBIONews ReleaseiBio and AstralBio Provide Update on Myostatin Program for Obesity
2024-09-20 16:05U:IBIONews ReleaseiBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
2024-09-03 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2024-08-12 16:30U:IBIONews ReleaseiBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development